The Drug-Induced Respiratory Disease Website
(Fr: OAP non cardiogénique). A.k.a. permeability edema. Typically acute and florid. Less often subaute/benign. PE often omplicates drug overdoses, particularly when given I.V. May accompany anaphylactic shock (PMID 29086053). May cause the ARDS picture. Drug-induced pulmonary edema cases generally have an acute or sudden onset, and are noncardiac (normal heart US and wedge pressure when measured) (NCPE). Transient fleeting pulmonary infiltrates were often reported as 'acute allergic pulmonary edema'. Hyperacute PE cases are sometimes called 'flash pulmonary edema' (see under IIi). Severe NCPE cases may exhibit the characteristic of ARDS (PMID 3532567, 15062601, 7555128, 1914570). The diagnosis of NCPE is raised when timing of the reaction is shortly (seconds to minutes) following administration of the causal drug or agent. NCPE is also a feature of anaphylaxis episodes (PMID 24376328). Patients with pulmonary hypertension are prone to the development of vasoldilator-induced NCPE (see under NO and other pulmonary vasodilator drugs). NCPE will generally relapse if the patient is reexposed to the drug. Note: overzealous administration of i.v. fluids or blood to a patient whose cardiocirculatory system cannot accomodate it may cause overload (hydrostatic) pulmonary edema (IIh) or TACO
Publications
Amphotericin B Associated Pulmonary Complications in Chronic Granulomatous Disease Patients.
Pediatric blood & cancer 2016 10;63;1871-2 — 2016 10 — 1871-2
Pulmonary reactions during treatment with amphotericin B: review of published cases and guidelines for management.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001 Oct 01;33;E75-82 — 2001 Oct 01 — E75-82
Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study.
BMJ (Clinical research ed.) 1998 Aug 08;317;379-84 — 1998 Aug 08 — 379-84
Life-threatening adverse event after amphotericin B lipid complex treatment in a patient treated previously with amphotericin B deoxycholate.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998 Apr;26;1016 — 1998 Apr — 1016
Cardiopulmonary toxicity after liposomal amphotericin B infusion.
Annals of internal medicine 1991 Apr 15;114;664-6 — 1991 Apr 15 — 664-6